Who
Michael S. Brown
Director
Company insider
Files Form 4 as: Director, Regeneron Pharmaceuticals; Director, Pfizer.
In numbers
- Trades disclosed
- 415
- Buys
- 0
- Sells
- 71
- Bought
- $0
- Sold
- $75.1M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 3 Jan 2006
- Last trade
- 30 Oct 2026
- Last filed
- 3 Nov 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Nov 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Oct 2026filed 3 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.4M1,929 at $725.89 | filing |
| 30 Oct 2026filed 3 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.7M1,929 at $875.00 | filing |
| 30 Oct 2026filed 3 Nov 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,929 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,958 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —166 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,535 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $960K1,535 at $625.60 | filing |
| 14 Jun 2024filed 17 Jun 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.6M1,535 at $1,040.00 | filing |
| 28 May 2024filed 29 May 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,172 at $0.00 | filing |
| 28 May 2024filed 29 May 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $733K1,172 at $625.60 | filing |
| 28 May 2024filed 29 May 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M1,172 at $974.86 | filing |
| 2 Jan 2024filed 4 Jan 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,607 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —135 at $0.00 | filing |
| 27 Dec 2023filed 29 Dec 2023 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,049 at $0.00 | filing |
| 27 Dec 2023filed 29 Dec 2023 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $989K2,049 at $482.68 | filing |
| 27 Dec 2023filed 29 Dec 2023 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.8M2,049 at $898.00 | filing |
News
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $812.00 Price Target at Sanford C. BernsteinREGN · themarketsdaily.com · 2 Nov 2026Regeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4 (NASDAQ:REGN)REGN · seekingalpha.com · 30 Oct 2026Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $980.00 Price Target at TD CowenREGN · themarketsdaily.com · 21 Oct 2026
0 headlines in the last 90 days name Michael S. Brown; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.